Mesothelioma
Pembrolizumab May Help Combat Mesothelioma
April 03, 2017Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.
Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma
June 29, 2016Undergoing pleurectomy and decortication for malignant pleural mesothelioma generally leads to improved quality of life after the surgery.
Modern Management of Malignant Pleural Mesothelioma
June 09, 2016[Lung Cancer: Targets and Therapy] This research evaluates the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM).
Combination of Live Bacterium and Chemotherapy Improves Response Rate in Patient With Pleural Mesothelioma
April 25, 2016Patients with malignant pleural mesothelioma (MPM) experienced greater than 90% disease control and 59% response rate after immunotherapy with live bacterium combined with chemotherapy.
Research Shows Drug Inhibits Mesothelioma Growth
April 01, 2016A new drug might help successfully treat mesothelioma, one of the deadliest cancers, according to results from cell culture and mouse xenograft models of the disease.
Tumor Weight and Volume May Improve Mesothelioma Staging Accuracy
February 15, 2016Improvements in scoring the severity of mesothelioma could be achieved by considering both tumor weight and volume.
Immunotherapy drug pembrolizumab shows promise for patients with mesothelioma
May 07, 2015The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in approximately 76% of patients with pleural mesothelioma.
Investigational personalized cellular therapy tolerated well by patients
May 04, 2015An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.
High-dose radiotherapy doesn't offer survival benefit in mesothelioma
October 17, 2014Treatnent with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to phase II trial data.
PD-L1 a possible immunotherapy target in mesothelioma
October 14, 2014Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.
Mesothelioma distinguished from noncancerous tissue by biomarkers
June 18, 2014Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma and noncancerous pleural tissue with reactive mesothelial proliferations.
Novel cancer vaccine promising against ovarian cancer and mesothelioma
March 27, 2014A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.
Radiation before surgery more than doubles mesothelioma survival
February 11, 2014Treating mesothelioma with radiation before surgery resulted in a 3-year survival rate that was more than double compared with that of treating with surgery first, according to new research.
Rib cage lymph nodes are prognostic for mesothelioma
November 15, 2013For the first time, researchers have shown the predictive power of a group of overlooked lymph nodes that could serve as a better tool to stage and ultimately treat patients with malignant pleural mesothelioma.
A roundup of FDA news from July 2013
August 02, 2013The FDA has granted orphan drug designation to a cancer stem cell inhibitor known as VS-6063, or defactinib, for use in the treatment of mesothelioma, a rare form of lung cancer.
Diagnosis delayed for certain cancers and certain patients
June 14, 2012A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.
Lung-sparing surgery/phototherapy combo improves survival in mesothelioma
June 16, 2011Lung-sparing surgery combined with photodynamic therapy (PDT) improved overall survival in patients with pleural mesothelioma compared with those treated with conventional therapy and PDT.
Kidney cancer drug may provide much-needed treatment for mesothelioma
May 13, 2011Temsirolimus, a kinase inhibitor commonly used to treat advanced renal cell carcinoma, may increase the effectiveness of chemotherapy administered in the treatment of mesothelioma.
ONA Articles
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Eating and Exercising Towards Better Health in Cancer Survivors
- Oral Cancer Medications: New Paradigm Brings New Challenges
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |